International Journal of Breast Cancer / 2018 / Article / Tab 2

Research Article

CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy

Table 2

Overall survival-3 years. This table shows an increase in overall survival after 3 years with tumors positive for CDK9 as compared to those negative for CDK9.

Overall survival (years)
CovariateLevelHazard RatioHR P-valueType3 P-value

CDK9 (Less than 3 years)Positive0.99 (0.30-3.23)0.9820.982
Negative-
CDK9 (Greater than 3 years)Positive0.26 (0.07-0.98)0.0460.046
Negative-

Number of observations in the original data set = 84.
Number of observations used = 67.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.